Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and Metastasis via Oxidative Stress, Mitophagy, and Aerobic Glycolysis

Stephanos Pavlides,^{1-5,*} Iset Vera,^{6,*} Ricardo Gandara,^{4,5} Sharon Sneddon,^{4,5} Richard G. Pestell,^{1-3,7} Isabelle Mercier,¹⁻³ Ubaldo E. Martinez-Outschoorn,^{1-3,7} Diana Whitaker-Menezes,¹⁻³ Anthony Howell,^{4,5} Federica Sotgia,¹⁻⁵ and Michael P. Lisanti^{1-5,7}

Abstract

Significance: Here, we review certain recent advances in oxidative stress and tumor metabolism, which are related to understanding the contributions of the microenvironment in promoting tumor growth and metastasis. In the early 1920s, Otto Warburg, a Nobel Laureate, formulated a hypothesis to explain the “fundamental basis” of cancer, based on his observations that tumors displayed a metabolic shift toward glycolysis. In 1963, Christian de Duve, another Nobel Laureate, first coined the phrase auto-phagy, derived from the Greek words “auto” and “phagy,” meaning “self” and “eating.” **Recent Advances:** Now, we see that these two ideas (autophagy and aerobic glycolysis) physically converge in the tumor stroma. First, cancer cells secrete hydrogen peroxide. Then, as a consequence, oxidative stress in cancer-associated fibroblasts drives autophagy, mitophagy, and aerobic glycolysis. **Critical Issues:** This “parasitic” metabolic coupling converts the stroma into a “factory” for the local production of recycled and high-energy nutrients (such as L-lactate)—to fuel oxidative mitochondrial metabolism in cancer cells. We believe that Warburg and de Duve would be pleased with this new two-compartment model for understanding tumor metabolism. It adds a novel stromal twist to two very well-established cancer paradigms: aerobic glycolysis and autophagy. **Future Directions:** Undoubtedly, these new metabolic models will foster the development of novel biomarkers, and corresponding therapies, to achieve the goal of personalized cancer medicine. Given the central role that oxidative stress plays in this process, new powerful antioxidants should be developed in the fight against cancer. *Antioxid. Redox Signal.* 16, 1264–1284.

Breast Cancer—General Knowledge

CANCER IS A MULTIFACTORIAL DISEASE caused by the combination of environmental, genetic, and behavioral factors. It is characterized by uncontrollable cell division, a change in cell morphology, and the ability of the cancer cell to develop an invasive phenotype.

Breast cancer is one of the major causes of cancer mortality in women. The incidence of breast cancer is still increasing worldwide. It is estimated that in the year 2011, there will be about 200,000 new cases of invasive breast cancer in the United States alone. These data translate to 1 in 8 (~12%)

women developing some form of breast cancer, over the course of their lifetime. About 5–10% of breast cancer cases are due to familial/inherited mutations within the BRCA1 or BRCA2 genes. Further, about 20–30% of women diagnosed with breast cancer have a family history of cancer. However, the most important risk factor for breast cancer is increased age (over 45 years old). Other risk factors can be prevented or modified, such as hormone use, low physical activity, alcohol consumption, diet, obesity, and smoking (2).

Breast cancer, like most cancers, is highly variable with great clinical heterogeneity. Gene profiling and high-throughput expression technologies have prompted the

Departments of ¹Stem Cell Biology & Regenerative Medicine and ²Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

³The Jefferson Stem Cell Biology and Regenerative Medicine Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

⁴Manchester Breast Centre & Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research and ⁵School of Cancer, Enabling Sciences and Technology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.

⁶Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York.

⁷Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

*Both authors are co-first authors.

classification of breast cancer into molecular subtypes, based on conventional markers, such as estrogen receptor (ER+), progesterone receptor (PR+), and human epidermal growth factor receptor (EGFR) 2 (Her2/Neu+) (28). In addition, classification can also be based on clinical outcome, response to therapy, and varied biological properties. Classification of breast cancer into subtypes is important to determine overall therapy, the clinical course of action, and patient prognosis.

The Tumor Microenvironment

Tumors are complex structures composed of multiple cell types, with the most prominent among these being the actual cancer cells, which exhibit a high or unlimited proliferative capacity. Cancer cells are surrounded by other cell types, which help to create and maintain the tumor microenvironment. There is an emerging interest in the role of the tumor microenvironment, since early studies have shown that the normal mammary microenvironment is capable of reversing the malignant nature of breast cancer cells, by inducing differentiation (23, 24). In the last decade the tumor microenvironment has received renewed attention for its role in supporting and even promoting the invasive cancer phenotype (Fig. 1).

The tumor microenvironment consists of immune cells (lymphocytes, natural killer cells, and antigen presenting cells), stromal cells (including myofibroblasts), and the vasculature (53). Together, these key components are known as the tumor stroma and account for nearly 50% of a tumor's mass (1). Myofibroblasts and/or cancer-associated fibroblasts (CAFs) are cells whose origin is yet not well defined, but it has been suggested that they arise from progenitors, such as mesenchymal stem cells (MSCs) derived from the bone marrow (BM) or from other differentiated cells, such smooth muscle cells, preexisting fibroblasts, and preadipocytes (83). MSCs are precursor cells that go on to become osteoblasts, chondrocytes, adipocytes, and fibroblasts, where they function in bone, car-

tilage, fat, and muscle morphogenesis, respectively (9). During injury, MSCs are dispatched to the site of injury, where they function in renewal and promote regeneration (9).

It is now well-recognized that cancer can be understood as "an injury that does not heal" (29, 104). Rudolf Virchow, in 1863, hypothesized that tumorigenesis requires a chronic irritation or a previous nonhealing wound (114), suggesting that cancer itself also promotes the attraction of mesenchymal cells to the tumor site (9). In support of this notion, CAFs have been shown to contribute to tumor growth by affecting cancer survival, (i) by generating antiapoptotic factors (91), (ii) by contributing to the vasculature by secreting vascular endothelial growth factor and angiopoietin, (iii) by promoting cell motility and metastasis through secretion of chemokines, such as CCL5 (54) and matrix metalloproteinases (MMPs), and (iv) by blocking the immune response through secretion of IL-6, IL-10 and TGF-beta (115).

Paracrine communication between CAFs and neighboring cancer epithelial cells is a crucial factor for the continued growth of the tumor mass (108). The tumor microenvironment also plays a role in resistance to radio/chemotherapy (3). In order to become more mobile, it is now accepted that cancer cells need to acquire mesenchymal-associated features, in a process known as an epithelial-mesenchymal transition (EMT) (127). CAFs seem to be playing a role in regulating the EMT, by either facilitating or inducing the EMT in cancer cells (42, 112, 113). This makes CAFs key player(s) in tumor progression, invasion, and metastasis.

The Warburg Effect

In the early 1920s, Otto Warburg, a Nobel Laureate (1931), formulated a hypothesis to explain the "fundamental basis" of cancer, based on his observations of tumor behavior where cancer cells displayed a metabolic shift toward glycolysis (116). Warburg stated that:

"Cancer, above all other diseases, has countless secondary causes. But, even for cancer, there is only one prime cause. Summarized in a few words, the prime cause of cancer is the replacement of the respiration of oxygen in the normal body cells by a fermentation of sugar."

In this hypothesis, referred to as the "Warburg Effect," cancer cells produce energy *via* the conversion of glucose into lactate, despite the presence of oxygen, a process known as aerobic glycolysis. Anaerobic glycolysis, in contrast, is initiated under hypoxic conditions in normal cells or when cancer cells adapt to hypoxia (22, 58, 110). Normal cells under aerobic conditions utilize glucose to produce pyruvate, which then gets oxidized in the mitochondria *via* the tricarboxylic acid (TCA) cycle into carbon dioxide, a process called oxidative phosphorylation (37).

Warburg's observations contrasted with the observations of Louis Pasteur. Sixty years before Warburg's time (1861), Pasteur described how in normal cells, the presence of oxygen normally inhibits glycolysis (47). The shift toward glycolysis, as a consequence of diminished oxygen, is also known as the "Pasteur effect" (85). By convention, aerobic glycolysis is less efficient for energy production (two ATP produced per molecule of glucose) compared to mitochondrial oxidative phosphorylation (36 ATP produced per molecule of glucose). Thus, aerobic glycolysis became a hallmark of the cancer phenotype.

FIG. 1. Stromal cancer-associated fibroblasts (CAFs) promote the growth of adjacent mammary epithelial cells, *via* the paracrine secretion of recycled nutrients. Here, we propose that loss of stromal caveolin-1 (Cav-1) expression is a hallmark of an aggressive mammary stromal phenotype that can be used as a biomarker to predict breast cancer recurrence and metastasis. DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma. Modified and reproduced with permission from Witkiewicz *et al.* (125). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

Despite nearly 85 years since it was first described, the Warburg effect remains a paradox within the scientific community and much effort has been invested to explain the basis for these observations. Warburg attributed this metabolic shift to mitochondrial dysfunction in cancer cells (116). However, several studies from the early 1970s found no evidence for a respiratory defect in cancer cells (30, 35, 75). For example, electron micrographs of tumors revealed the presence of mitochondria in epithelial cancer cells, which contrasted with the neighboring fibroblasts (84). With the advent of cell culture techniques, investigations in tumor biology and respiratory chain activity have been carried out, using immortalized cancer cell lines (101, 105, 111). These studies demonstrated that the increased growth rate of cancer cells is a consequence of an increased glycolytic rate (glycolytic shift), prompting a decrease in oxidative phosphorylation and mitochondrial density. Simonnet *et al.*, in particular, concluded that tumor cells with increased mitochondrial dysfunction exhibited a more aggressive phenotype (105).

As a consequence of the Warburg effect, cancer cells would produce large amounts of lactate. The excess lactate is then released to the extracellular environment which results in a decrease in extracellular pH. This acidic microenvironment is thought to favor the metastatic potential of some cancer cells (46, 102). Another recent explanation for this paradox proposes that such a metabolic shift is beneficial for proliferating cells that require, in addition to energy in the form of ATP, macromolecules such as nucleotides, amino acids, and lipids. In this explanation, glycolytic intermediates promote increased growth rate through the incorporation of carbon sources, such as glucose, into the biomass and thus contribute to a balance between catabolic and anabolic needs of actively proliferating cells (110). Despite extensive research, there is still no consensus on why cancer cells would use an inherently inefficient process to meet their ever-increasing energy demands.

Autophagy

In 1963, Christian de Duve, a Nobel Laureate, first coined the phrase auto-phagy, derived from the Greek words "auto" and "phagy," meaning "self" and "eating." Autophagy is an evolutionarily conserved survival pathway involving degradation of cytoplasmic constituents, the recycling of ATP, and the maintenance of cellular biosynthesis, during nutrient deprivation or metabolic stress (17). Autophagy plays an important homeostatic role, mediating removal, digestion, and recycling of damaged organelles (73, 74). Autophagy is activated in response to a range of stimuli, including nutrient depletion, hypoxia, and activated oncogenes. Autophagy has also been shown to play a dual role: (i) it results in consumption of cellular components and subsequent cell death (5); (ii) it is able to maintain cancer cell survival under conditions of metabolic stress, and it may confer resistance to radiation and chemotherapy (4, 25).

Autophagy can provide a survival advantage to tumors by overcoming metabolic stress during tumorigenesis. Tumor cells are frequently exposed to metabolic stress owing to hypoxia and nutrient deprivation and autophagy can help maintain essential cellular functions through its recycling capacity. In addition, there is an increase in hypoxia-inducible transcription factor 1- α (HIF1- α), which promotes

autophagy (through BNIP3) and angiogenesis (7, 128). HIF1-dependent expression of BNIP3 is essential for the selective autophagy of mitochondria, also called mitophagy. Hypoxia can also activate autophagy through HIF1-independent pathways (26). Understanding the mechanisms of autophagy in different cells of the tumor microenvironment is an essential prerequisite for developing an autophagy-activating or autophagy-inhibiting treatment strategy.

Caveolin-1 and CAFs

Caveolins are a family of scaffolding proteins that are involved in several cellular processes, such as cholesterol homeostasis, vesicular transport, and the regulation of signal transduction (18, 120). The Caveolin-1 (Cav-1) gene is located in close proximity to the D7S522 locus, which is frequently deleted in various human cancers, including tumors of the breast, colon, ovary, and head and neck (120). Cav-1 mRNA and protein are downregulated or absent in primary human cancers and numerous cancer cell lines (56). Cav-1 is a negative regulator of cytokine receptor signaling and various studies indicate contrasting tumor suppressor and tumor promoter functions, depending on the tumor cell type studied (43, 120). Tumor microarray (TMA) analysis of invasive breast carcinomas identifies Cav-1 overexpression to be associated with a basal-like phenotype, predicting a worse prognosis in breast cancer patients (95, 103) and hepatocellular carcinomas (129). Cav-1 is also reduced in human ovarian cancer suggesting a role as tumor suppressor (118).

We have shown that Cav-1 expression is significantly reduced in human breast CAFs, compared with matched normal mammary fibroblasts obtained from the same patients (70). In this study, CAFs were isolated from 11 breast cancer patients, 8 of which showed a significant downregulation of Cav-1 at the protein level, but not at the transcriptional level (70). To validate a correlation between decreased Cav-1 expression in CAFs and mammary stromal fibroblasts lacking Cav-1, we performed *in vitro* experiments to demonstrate a direct cause-effect relationship (108). Human CAFs and mammary stromal fibroblasts obtained from Cav-1 $-/-$ null mice share many characteristics such as hyperproliferation, increased collagen production, and activated TGF- β signaling, the upregulation of muscle-related genes, and the ability to contract/retract (108). Further, genome-wide expression profiling showed common transcriptional characteristics between the human breast CAFs and the Cav-1 $-/-$ mammary stromal fibroblasts (86–89, 108). These shared phenotypic characteristics are hallmarks of a constitutive myofibroblastic phenotype.

CAFs are suggested to play an important role in mediating paracrine signaling to mammary epithelial-derived tumor cells (96, 97). In support of this, we recently showed that conditioned media prepared from Cav-1 $-/-$ mammary stromal fibroblasts promotes an EMT, blocks the typical 3D acinar structure formation of epithelial cells, and induces instead a mesenchymal appearance, with the induction of smooth muscle actin expression (108). The EMT is a major characteristic of cancer progression toward a metastatic phenotype (50, 108). In agreement with the above findings, in *in vivo* transplant studies, there is a two-fold increased growth of mammary tumor cells, when these are implanted in the mammary fat pad of Cav-1 $-/-$ deficient mice (122). Taken

together, these studies directly demonstrate the association between mammary stromal fibroblasts lacking Cav-1, and the cancer-associated fibroblastic phenotype (70, 108). Thus, Cav-1^{-/-}-deficient mammary fibroblasts represent a valid experimental model for the study of CAF biology in cancer progression (108).

Cav-1 in Human Tumor Samples: New Stromal Biomarker Discovery

Although Cav-1 appears to have both tumor-suppressive and promoter activity in different cancers, studies have suggested that Cav-1 inhibits breast cancer cell migration and metastasis (14, 34, 39, 40, 56, 107, 120). Cav-1-null mice carrying the MMTV-PyMT transgene develop an increased number of dysplastic lesions throughout the mammary gland and lung metastasis is dramatically enhanced (119–121). Further, Cav-1 expression levels are significantly lower in human breast cancer cells, than in their normal mammary epithelial cell counterparts (60).

All of this experimental and clinical evidence supports the idea that Cav-1 is a tumor suppressor in patients with breast cancer. To test whether loss of stromal Cav-1 could serve as a biomarker for prognostic and diagnostic analysis, several independent studies were carried out using various human breast cancer cohorts. In one study, a cohort of 78 ductal carcinoma *in situ* (DCIS) patients was evaluated for the presence of Cav-1 in the breast cancer tumor stroma. These patients were treated with wide excision, but without any chemo- or radiotherapy, thus ruling out other variables due to treatment. These findings directly demonstrated that a loss of stromal Cav-1 is a powerful predictor of DCIS recurrence and progression to invasive breast cancer. Moreover, analysis of the DCIS lesions revealed that a loss of stromal Cav-1 showed increased inflammatory cells at the lesion site. On the other hand, ER⁺ patients with high levels of Cav-1 expression in their tumor stroma showed no recurrence and no progression (123). Thus, in this study, the prognostic value of Cav-1 as a biomarker in early breast lesions was established, indicating that stromal Cav-1 could be used nearly 15–20 years in advance, to predict the onset of DCIS recurrence and progression to invasive breast cancer (123).

Importantly, the predictive value of a loss of stromal Cav-1 is independent of epithelial marker status, indicating that it is a useful biomarker in all the most common epithelial subtypes of human breast cancer, including ER⁺, PR⁺, HER2⁺, and triple-negative breast cancers (Figs. 2 and 3). For example, a TMA of 154 patients with invasive carcinoma was analyzed to determine the correlation of loss of stromal Cav-1, with patient outcome, and other clinical and pathological variables. Importantly, an absence of stromal Cav-1 correlated with early tumor recurrence, lymph node metastasis, and advanced tumor stage. In addition, an absence of stromal Cav-1 expression was particularly predictive in lymph node positive (LN⁺) patients. In this group of LN⁺ patients, high stromal levels of Cav-1 were associated with a 5-year survival rate of >80%. In contrast, an absence of stromal Cav-1 was predictive of a 5-year survival rate of ~7%, an 11.5-fold stratification (125). In addition, a loss of stromal Cav-1 was positively correlated with treatment failure in ER⁺ patients who received tamoxifen, indicative of resistance to endocrine-related therapies (125).

FIG. 2. Stromal Cav-1 expression in human breast cancer tissue. Breast tumor samples were immunostained with antibodies directed against Cav-1 and subjected to scoring. Representative examples are shown. Stromal Cav-1 was scored for each tissue sample based on three cores taken from the sample and given a numeric score of 0, 1, or 2, depending on the degree of stromal Cav-1 staining. The median of the three numeric scores was taken to be the stromal Cav-1 score for the sample. A median score of 0 was interpreted as an absence of stromal Cav-1, and scores of 1 and 2 were interpreted as the presence of stromal Cav-1. It is important to note that loss of stromal Cav-1 staining was independent of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in breast cancer cells. Modified and reproduced with permission from Witkiewicz *et al.* (125). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

To further scrutinize the importance of Cav-1 as a predictive tool in late-stage carcinoma, a TN (triple negative; ER⁻; PR⁻; HER2⁻) cohort was specifically tested for Cav-1 expression and correlated this with the overall survival of patients based on 12 years of accumulated outcome data. In this context, TN patients with high stromal Cav-1 had a 5-year survival rate >75%, while <10% survived when Cav-1 was absent in the tumor stroma (124) (Fig. 4). Further, after comparison with other established TN and basal breast cancer markers such as cytokeratin 5/6 (CK5/6) (+) and EGFR (+), a loss of stromal Cav-1 was substantiated as a robust and valuable prognostic factor.

To identify and characterize the signaling pathways that are activated in a Cav-1-negative tumor microenvironment, the fibroblastic stroma was laser-capture microdissected from four cases showing high stromal Cav-1 expression and seven cases with a loss of stromal Cav-1. Transcriptional analysis identified 238 gene transcripts that were upregulated and 232 gene transcripts that were downregulated in the stroma of tumors showing a loss of Cav-1 expression ($p \leq 0.01$ and fold-change ≥ 1.5). Gene set enrichment analysis revealed that

Stromal Caveolin-1 (Cav-1) as a Breast Cancer Biomarker

FIG. 3. An absence of stromal Cav-1 expression predicts early tumor recurrence and poor clinical outcome in breast cancers. Note that stromal Cav-1 is a powerful predictive biomarker for estimating a patient's risk of recurrence and survival in all of the four most common classes of breast cancer, which are based on ER, progesterone receptor (PR), and HER2 expression. Its behavior in tamoxifen-treated *versus* non-tamoxifen-treated patients is also shown for comparison. An asterisk (*) denotes statistical significance. Five-year progression-free survival is indicated by an arrow. *p*-Values ranged from 10^{-9} to 10^{-2} , depending on the patients selected for analysis. Modified and reproduced with permission from Witkiewicz *et al.* (125).

these transcripts were associated with "stemness," inflammation, DNA damage, aging, oxidative stress, hypoxia, autophagy, and mitochondrial dysfunction in the stroma of Cav-1-negative patients (126) (Fig. 5). These results are consistent with previous biomarker studies showing that increased expression of autophagy markers, such as ATG16L, in the tumor stroma is specifically associated with metastatic tumor progression and/or poor clinical outcome (82).

The importance of a loss of stromal Cav-1 in regard to breast cancer invasiveness (metastasis) and survival was recently independently validated by two other research groups, using different antibody probes and distinct breast cancer patient populations, in Australia, Argentina, and Korea (57, 106). Similarly, in Japan, a third research group showed that a loss of Cav-1 in the stroma (coupled with positive expression of Cav-1 in the tumor cells) is significantly correlated with an unfavorable prognostic outcome in breast cancer (98).

Moreover, a loss of stromal Cav-1 could serve as a universal or widely applicable biomarker in other epithelial cancers, since similar observations were also now validated in advanced and metastatic prostate cancer (27). In this cohort, a loss of stromal Cav-1 strictly correlated with a high Gleason score, the current gold standard for predicting clinical outcome in prostate cancer patients (27).

The Reverse Warburg Effect Drives Tumor-Stroma Metabolic Coupling

Given the powerful predictive value of a loss of stromal Cav-1 in human breast and prostate cancer patients, we decided to pursue the discovery of new biomarkers that were associated with a lack of Cav-1 expression in the tumor stroma cells. As an initial approach to identify upregulated proteins in the Cav-1^{-/-} stromal cells, we carried out an unbiased proteomics analysis using BM mesenchymal stromal cells derived from Cav-1^{-/-} null and wild-type mice (89). We chose this approach as it has been shown that CAFs at tumor sites originate from precursor stromal cells of the BM (6, 44, 72). We examined both cell lysates to identify proteins within cells, as well as conditioned media, to identify secreted proteins. In addition, gene expression profiling using the Affymetrix exon array was carried out to provide independent validation of the proteomics data. Analysis of this new model of CAFs (Cav-1^{-/-}-deficient stromal cells) specifically showed the upregulation of glycolytic enzymes (PKM2, LDH-A), myofibroblastic markers (vimentin, calponin), extracellular matrix (ECM) proteins (collagen, SPARC), signaling molecules (annexins A1, A2, and RhoGDI), oncogenes (EF1- δ), liver-specific proteins (albumin, fetoprotein), and

FIG. 4. Prognostic value of Cav-1 as a stromal biomarker for triple-negative breast cancer. Kaplan-Meier analysis of stromal Cav-1 predicts overall survival in a second independent cohort of triple-negative (TN) breast cancer patients. Patients with high levels of stromal Cav-1 (score=2) had a good clinical outcome, with 75.5% of the patients remaining alive during the follow-up period (nearly 12 years). In contrast, the median survival for patients with absent stromal Cav-1 staining (score=0) was 25.7 months. The results of this analysis were highly statistically significant ($p=2.8 \times 10^{-6}$). Modified and reproduced with permission from Witkiewicz *et al.* (124). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

antioxidant enzymes (catalase, peroxiredoxin-1) (89). The biological relevance of these observations was further validated by directly immunostaining breast cancer tissue sections derived from patients with a loss of stromal Cav-1 (89).

The most important observation from this study is that a panel of glycolytic markers (such as PKM2, LDH, enolase, and fructose-bisphosphate aldolase A) were all seen to be upregulated in Cav-1-deficient stromal cells, both at the protein and mRNA transcript level, which led us to consider that the Warburg effect might actually originate in the tumor stroma, and not in epithelial cancer cells (89). This has important physiological consequences, as it means that glycolytic cancer associated fibroblasts would function as factories to convert glucose to L-lactate, a high-energy metabolite. In turn, the L-lactate could then be transferred to oxidative cancer cells, which then would generate large amounts of ATP, *via* the TCA cycle, and oxidative mitochondrial metabolism. In this scenario, epithelial cancer cells are parasites that hijack neighboring normal stromal cells as a fuel supply. To distinguish this new idea from the conventional Warburg effect, we have coined the term, the “reverse Warburg effect,” where cancer cells steal energy *via* aerobic glycolysis in the tumor stroma (Figs. 6 and 7) (89). Consistent with the idea that Cav-1-deficient tumor stroma is highly glycolytic, it stains positively for BNIP3L (a marker of mitochondrial dysfunction; Fig. 8) and monocarboxylate transporter 4 (MCT4) (a marker of L-lactate production and secretion; Fig. 9) in human breast cancer samples (68, 117).

A more in-depth analysis of the Cav-1-deficient transcriptional data obtained from the above study (89) was performed using a bioinformatics approach to reinterrogate and intersect our transcriptional data, with previously published data sets, to identify specific transcriptional patterns (87). In this context, several interesting and relevant transcriptional signatures and biological processes emerged, which included gene sets associated with aging, inflammation, DNA damage, oxidative stress, nitric oxide (NO) overproduction, glycolysis, and mitochondrial dysfunction. Similarly, we also observed the upregulation of key reactive oxygen species (ROS)-producing enzymes, and the critical targets of transcription factors normally associated with oxidative stress, such as NFkB (innate immune response) and HIF1- α (hypoxia, glycolysis, and mitochondrial dysfunction) (87).

How does a loss of stromal Cav-1 have such powerful effects on gene expression profiling? One idea is that this is mostly secondary to the overproduction of NO, which acts as a mitochondrial “poison.” Cav-1 normally functions as known negative regulator of NO production, *via* the tonic inhibition of nitric oxide synthase (NOS). Thus, a loss of stromal Cav-1 would drive NO overproduction. In turn, NO overproduction can directly drive mitochondrial dysfunction, as it interferes with proper oxidative phosphorylation, leading to increased mitochondrial ROS production, and driving oxidative stress which mimics hypoxia (also known as pseudohypoxia). This would then account for the observed increases in gene profiles associated with aging, DNA damage, inflammation, glycolysis, as well as NFkB and HIF1- α activation (87).

Previously, we and others have shown that Cav-1 is a negative regulator of NOS (41, 52, 100). In our working model, Cav-1 downregulation leads to increased NOS activity leading to excess NO production. NO at normal levels is an important signaling molecule for modulating inflammatory response (16); however, in excess amounts, accumulation of NO can be deleterious to cells by promoting ROS production (8).

It has been shown that excess NO causes mitochondrial dysfunction through increased nitrosative stress and the production of peroxynitrite (10, 45, 55, 99), and we demonstrated that Cav-1 $^{-/-}$ stromal cells have increased protein tyrosine nitration, which is a functional indicator of excess of NO production and oxidative stress. We showed this at the whole cell level *via* immunofluorescence to detect nitro-tyrosinated proteins (87). In particular, we also showed *via* immunoprecipitation studies of BM-derived stromal cells and siRNA-treated fibroblasts that mitochondrial components (such as complex-I) undergo increased tyrosine nitration in the absence of Cav-1 (87). Increased tyrosine nitration of mitochondrial components, such as complex-I, is indicative of mitochondrial dysfunction and oxidative stress (10, 15, 45, 99).

In accordance with this view, previous studies have shown that Cav-1 $^{-/-}$ null mice have functional mitochondrial defects and reduced mitochondrial reserve capacity (18–20). For example, Cav-1 $^{-/-}$ white adipose tissue was shown to have mislocalized mitochondria and abnormal triglyceride hydrolysis, which is an indication of an inability to utilize fatty acids in the mitochondria (19). In a separate study, looking at brown adipose tissue (BAT), it was shown that mice lacking Cav-1 have defects in thermoregulation, since metabolic restriction (starvation) coupled with cold treatment caused Cav-1 null mice to be unable to maintain their body temperature (20).

FIG. 5. Loss of Cav-1 in the tumor stroma of human breast cancer patients is associated with aging, DNA damage, inflammation, cancer metabolism, and autophagy. (A) The transcriptional profiles of Cav-1-positive (+) tumor stroma ($n=4$) versus Cav-1-negative (-) tumor stroma ($n=7$) were compared, *via* laser-capture microdissection. Note that Cav-1-deficient stroma shows the upregulation of aging (73 transcripts), the DNA damage response (67 transcripts), NFκB signaling (11 transcripts), the immune response (31 transcripts), hypoxia-inducible transcription factor 1 (HIF1)/hypoxia target genes (65 transcripts), glycolysis/pyruvate metabolism (15 transcripts), and autophagy (22 transcripts). In human breast cancer patients, a loss of stromal Cav-1 is associated with early tumor recurrence, lymph node metastasis, drug resistance, and overall poor survival, conferring a lethal tumor microenvironment. A schematic diagram summarizing these results is presented in *panel B*. See the text for details. Modified and reproduced with permission from Witkiewicz *et al.* (126). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

FIG. 6. Epithelial tumor cells induce oxidative stress in CAFs (Step 1). Note that reactive oxygen species (ROS) production in cancer cells is transferred to adjacent fibroblasts, initiating the onset of stromal oxidative stress, autophagy, and mitophagy, due to the activation of key transcription factors, namely HIF1- α (aerobic glycolysis) and NF κ B (inflammation). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

This is an indication of a defect in mitochondrial function where fatty acid liberation and fatty acid beta-oxidation (a mitochondrial process) does not occur in these mice (20). Further, electron microscopy revealed defects in mitochondrial morphology with enlarged and dilated mitochondria in the BAT of Cav-1^{-/-} mice (20). Similarly, another study demonstrated that Cav-1^{-/-} null mice that have undergone partial hepatectomy are unable to regenerate their liver, resulting in lethality (36). This fatal outcome is prevented when these mice are provided with increased glucose, but not fatty acids. As such, it appears that Cav-1-deficient mice are strictly dependent on glucose and aerobic glycolysis for energy production, rather than mitochondrial function and beta-oxidation (36). Mitochondrial dysfunction in Cav-1-deficient mice may also be caused due to increased cholesterol accumulation in mitochondrial membranes, which leads to a loss of efficiency of mitochondrial respiratory chain and increased ROS production (13). Therefore, these examples demonstrate that a Cav-1 deficiency leads to mitochondrial dysfunction in various cell types, under stressful conditions.

As Cav-1^{-/-}-deficient mice represent a "whole body" animal model of mitochondrial dysfunction in the tumor micro-

environment, this could lead to the development of new strategies for anticancer therapy (87). For example, we could target the tumor stroma with inhibitors of glycolysis and mitochondrial oxidative phosphorylation. To validate this working hypothesis, we carried out *in vivo* studies using conventional inhibitors of glycolysis (2-deoxy-glucose [2DG]) and mitochondrial metabolism (metformin; a mitochondrial complex I inhibitor), to block the two arms of energy production and test the mitochondrial reserve capacity of Cav-1^{-/-} null mice (87). For this purpose, mice were treated daily with both inhibitors for up to 2 weeks. Importantly, Cav-1^{-/-} null mice were extremely sensitive to the treatment; 80% of the mice died within 24 h, and 100% died within 48 h (87). However, all wild-type mice survived the entire treatment period (87). Thus, a Cav-1 deficiency is synthetically lethal with energy restriction, possibly explaining the tumor suppressor effects of caloric restriction. It is important to note that treatment with 2DG alone or metformin alone was not lethal in Cav-1 null mice, indicating that the combination was indeed required for effective chemical induction of energy restriction.

In further support of these findings, a separate study from our laboratory used a novel human tumor xenograft model to

FIG. 7. The onset of stromal-epithelial metabolic coupling fuels the Warburg effect in fibroblasts and oxidative mitochondrial metabolism in cancer cells (Step 2). Note that in this model, autophagic-glycolytic fibroblasts secrete both recycled and high-energy nutrients (such as ketone bodies and L-lactate, as well as glutamine). Then, cancer cells use these nutrients to fuel oxidative mitochondrial metabolism, to generate large amounts of ATP and protect themselves against apoptosis. ROS production in fibroblasts also promotes mutagenesis and genomic instability in cancer cells, driving tumor-stroma coevolution. At the same time, the cancer cells mount an antioxidant defense, by overexpressing certain key antioxidant proteins, such as the peroxiredoxins and TIGAR. (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

mechanistically address the reverse Warburg effect *in vivo* (12). Aggressive human breast cancer cells, MDA-MB-231, were coinjected in nude mice with WT or Cav-1-deficient stromal fibroblasts. Fibroblasts lacking Cav-1 specifically promoted tumor growth, with a ~2.5-fold increase in both tumor weight and volume (12). Interestingly, treatment of this Cav-1-deficient xenograft model with a combination of two glycolysis inhibitors, namely 2DG and dichloro-acetate (DCA), reduced tumor growth by ~4.5-fold (12). Thus, this demonstrates a promising new therapeutic strategy for breast cancer patients who lack stromal Cav-1 expression (12).

Further, several follow-up studies from our laboratory have now validated and contributed to a better mechanistic understanding of this hypothesis. Well-established fibroblast cell lines were used to show that tumorigenesis is enhanced in the presence of glycolytic fibroblasts *versus* fibroblasts that use oxidative respiration (71). These glycolytic fibroblasts showed an increase in vimentin expression and a loss of Cav-1, consistent with both myofibroblastic differentiation and the reverse Warburg effect, respectively (71). Interestingly, these glycolytic fibroblasts also dramatically promoted tumor growth, with a ~4-fold increase in tumor mass and ~8-fold

increase in tumor volume, as assessed using the MDA-MB-231 xenograft model (71).

Using an informatics approach, we next compared our gene profiling data from Cav-1-deficient MSCs (89) with existing transcriptional data from human breast cancer tumor stroma (38). This strategy allowed us to show that these two data sets have considerable overlap, indicating that Cav-1-deficient stromal cells have a similar transcriptional profile to *bona fide* tumor stroma from human breast cancers (88). In addition, these two gene profiles (from Cav-1-deficient stromal cells and the tumor stroma) showed significant overlap with the Alzheimer's disease brain gene set, consistent with the idea that all three gene sets are associated with inflammation and oxidative stress (88). These data also suggest that loss of Cav-1 expression in CAFs could be used as a surrogate marker for oxidative stress, aerobic glycolysis, and inflammation in the tumor microenvironment (88).

In this context, it is interesting to note that the brain also uses a form of metabolic coupling, analogous to the one we have proposed for the reverse Warburg effect. This idea was first proposed ~10–15 years ago, and is known as

FIG. 8. BNIP3L, a marker of autophagy and mitochondrial dysfunction, is selectively increased in the stroma of human breast cancers. Paraffin-embedded sections of human breast cancer samples lacking stromal Cav-1 were immunostained with antibodies directed against BNIP3L. Slides were then counterstained with hematoxylin. Note that BNIP3L is highly expressed in the stromal compartment of human breast cancers that lack stromal Cav-1. Two representative images are shown. Original magnification, 40× and 60×, as indicated. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (68). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

Neuron-Glia metabolic coupling (62–64, 90, 109). In this model, astrocytes display a glycolytic shift and secrete lactate and pyruvate, high-energy metabolites, which directly feed neurons. Thus, the shuttling of high-energy lactate from one cellular compartment to another is a normal physiological mechanism, which tumors have copied, resulting in epithelial-stromal metabolic coupling.

Another prediction of this hypothesis is that CAFs should express MCT4, a monocarboxylate transporter that has been implicated in lactate efflux. MCF7 breast cancer cells were cocultured with normal fibroblasts and it was shown that breast cancer cells specifically induced the expression of MCT4 in CAFs; whereas in monoculture, neither cell type expressed MCT4 (117). Further experiments showed that the induction MCT4 in CAFs is due to oxidative stress or pseudohypoxia and treatment with antioxidants such as N-acetylcysteine (NAC) was sufficient to block this upregulation (117). This points toward the idea that accumulation of MCT4 in CAFs is a marker of oxidative stress. Interestingly, MCT1 (another lactate transporter) was found to be specifically upregulated in MCF7 breast cancer cells, when cocultured with fibroblasts. Similar results were obtained with primary human breast cancer

FIG. 9. Monocarboxylate transporter (MCT4), a marker of aerobic glycolysis and lactate production, is selectively increased in the stroma of human breast cancers. Paraffin-embedded sections of human breast cancer samples lacking stromal Cav-1 were immunostained with antibodies directed against MCT4. Note that MCT4 staining is selectively localized to the fibroblastic tumor stromal compartment of human breast cancers. Two representative images are shown. Both clearly show that MCT4 staining is absent from the tumor epithelial cells, but is present in the surrounding stroma. MCT4 staining outlines the CAFs that surround nests of epithelial cancer cells. Original magnification, 40× and 60×, as indicated. Modified and reproduced with permission from Whitaker-Menezes *et al.* (117). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

samples. In human breast cancers, MCT4 is specifically expressed in CAFs (Fig. 9), but MCT1 was selectively expressed in the epithelial cancer cells, within the same tumors, suggesting that expression of both transporters in separate cellular compartments could confer a survival advantage for human tumors (117). These findings provide the first evidence for the existence of a stromal-epithelial lactate shuttle in human tumors (117).

MCT1 has also been found to be overexpressed in lung cancer cell lines (51), colorectal carcinomas (94), and during progression to invasive cervical carcinoma (93), suggesting that cancer cells may be utilizing lactate in more than conventional ways. These findings all seem to point to the occurrence of the reverse Warburg effect. MCT1, but not MCT4, has also been reported to be upregulated in a set of patients with basal-like breast carcinoma (92). This suggests that breast epithelial cancer cells are not glycolytic, but instead they import lactate possibly to be used as fuel for the TCA cycle and oxidative phosphorylation as described by the reverse Warburg effect (Table 1) (12).

TABLE 1. GENE SET ENRICHMENT ANALYSIS: TRANSCRIPTS ASSOCIATED WITH OXIDATIVE MITOCHONDRIAL METABOLISM ARE UPREGULATED IN HUMAN BREAST CANCER CELLS, RELATIVE TO ADJACENT STROMAL CELLS *IN VIVO*

<i>Gene set</i>	<i>Description</i>	<i>p-Value</i>
Oxidative phosphorylation		
HSA00190_OXIDATIVE_PHOSPHORYLATION	Genes involved in oxidative phosphorylation	Less than 1.00E-16
MOOTHA_VOXPPOS	Oxidative phosphorylation	Less than 1.00E-16
ELECTRON_TRANSPORT_CHAIN	Genes involved in electron transport	Less than 1.00E-16
OXIDATIVE_PHOSPHORYLATION	OXIDATIVE_PHOSPHORYLATION	3.81E-14
UBIQUINONE_BIOSYNTHESIS	UBIQUINONE_BIOSYNTHESIS	1.55E-06
Mitochondrial genes		
MITOCHONDRION	Genes annotated by the GO term GO:0005739.	Less than 1.00E-16
A semiautonomous, self-replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.		
HUMAN_MITODB_6_2002	Mitochondrial genes	Less than 1.00E-16
MITOCHONDRIA	Mitochondrial genes	Less than 1.00E-16
MITOCHONDRIAL_PART	Genes annotated by the GO term GO:0044429.	2.22E-16
Any constituent part of a mitochondrion, a semiautonomous, self-replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.		
MITOCHONDRIAL_MEMBRANE	Genes annotated by the GO term GO:0031966.	3.77E-15
Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope.		
MITOCHONDRIAL_ENVELOPE	Genes annotated by the GO term GO:0005740.	1.17E-14
The double lipid bilayer enclosing the mitochondrion and separating its contents from the cell cytoplasm; includes the intermembrane space.		
MITOCHONDRIAL_INNER_MEMBRANE	Genes annotated by the GO term GO:0005743.	2.01E-13
The inner, that is, lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae.		
MITOCHONDRIAL_MEMBRANE_PART	Genes annotated by the GO term GO:0044455.	1.53E-12
Any constituent part of the mitochondrial membrane, either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope.		
MITOCHONDRIAL_RESPIRATORY_CHAIN	Genes annotated by the GO term GO:0005746.	4.42E-07
The protein complexes that form the mitochondrial electron transport system (the respiratory chain). Complexes I, III, and IV can transport protons if embedded in an oriented membrane, such as an intact mitochondrial inner membrane.		
MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I	Genes annotated by the GO term GO:0005747.	2.09E-05
A part of the respiratory chain located in the mitochondrion. It contains about 25 different polypeptide subunits, including NADH dehydrogenase (ubiquinone), flavin mononucleotide, and several different iron-sulfur clusters containing non-heme iron. The iron undergoes oxidation-reduction between Fe(II) and Fe(III), and catalyzes proton translocation linked to the oxidation of NADH by ubiquinone.		
NADH_DEHYDROGENASE_COMPLEX	Genes annotated by the GO term GO:0030964.	2.09E-05
An integral membrane complex that possesses NADH oxidoreductase activity. The complex is one of the components of the electron transport chain. It catalyzes the transfer of a pair of electrons from NADH to a quinone.		
RESPIRATORY_CHAIN_COMPLEX_I	Genes annotated by the GO term GO:0045271.	2.09E-05
Respiratory chain complex I is an enzyme of the respiratory chain. It consists of at least 34 polypeptide chains and is L-shaped, with a horizontal arm lying in the membrane and a vertical arm that projects into the matrix. The electrons of NADH enter the chain at this complex.		
TCA/citric acid cycle		
TCA	TCA-related genes	6.10E-06
CITRATE_CYCLE_TCA_CYCLE	CITRATE_CYCLE_TCA_CYCLE	1.35E-05

(continued)

TABLE 1. (CONTINUED)

Gene set	Description	p-Value
KREBS_TCA_CYCLE	KREBS_TCA_CYCLE	1.99E-05
HSA00620_PYRUVATE_METABOLISM	Genes involved in pyruvate metabolism	3.32E-05
HSA00020_CITRATE_CYCLE	Genes involved in citrate cycle (TCA cycle)	3.82E-07
Biosynthesis and energy		
CELLULAR_BIOSYNTHETIC_PROCESS	Genes annotated by the GO term GO:0044249.	3.56E-13
The chemical reactions and pathways resulting in the formation of substances, carried out by individual cells.	Genes annotated by the GO term GO:0009058.	4.74E-11
BIOSYNTHETIC_PROCESS	Genes annotated by the GO term GO:0009059.	2.38E-10
The energy-requiring part of metabolism in which simpler substances are transformed into more complex ones, as in growth and other biosynthetic processes.	Genes annotated by the GO term GO:0009059.	
MACROMOLECULE_BIOSYNTHETIC_PROCESS	Genes annotated by the GO term GO:0009059.	
The chemical reactions and pathways resulting in the formation of macromolecules, large molecules including proteins, nucleic acids, and carbohydrates.	ATP_SYNTHESIS	1.64E-05
ATP_SYNTHESIS	PURINE_METABOLISM	1.21E-06
PURINE_METABOLISM	PYRIMIDINE_METABOLISM	6.39E-05
Nutrient starvation		
PENG_LEUCINE_DN	Genes downregulated in response to leucine starvation	Less than 1.00E-16
PENG_GLUTAMINE_DN	Genes downregulated in response to glutamine starvation	Less than 1.00E-16
PENG_GLUCOSE_DN	Genes downregulated in response to glucose starvation	2.09E-08
Alzheimer's disease and aging		
ALZHEIMERS_DISEASE_DN	Downregulated in correlation with overt Alzheimer's disease, in the CA1 region of the hippocampus	Less than 1.00E-16
ALZHEIMERS_INCIPIENT_DN	Downregulated in correlation with incipient Alzheimer's disease, in the CA1 region of the hippocampus	3.05E-10
AGED_RHESUS_DN	Downregulated in the vastus lateralis muscle of aged <i>vs.</i> young adult rhesus monkeys	3.30E-09
AGED_MOUSE_CORTEX_DN	Downregulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls	2.78E-06
OLD_FIBRO_DN	Downregulated in fibroblasts from old individuals, compared to young	2.42E-05
Hypoxia		
MANALO_HYPOXIA_DN	Genes downregulated in human pulmonary endothelial cells under hypoxic conditions or after exposure to AdCA5, an adenovirus carrying constitutively active hypoxia-inducible factor 1 (HIF-1alpha).	1.38E-06

Note that mRNA transcripts associated with oxidative mitochondrial metabolism are upregulated in human breast cancer cells, relative to adjacent stromal cells. Note also that breast cancer cells are not undergoing nutrient starvation, hypoxia, or accelerated aging (oxidative stress), as similarities with the down (DN) gene sets are observed. Modified and reproduced with permission from Bonuccelli *et al.* (12).

OXPHOS, oxidative phosphorylation; PR, progesterone receptor; TCA, tricarboxylic acid.

FIG. 10. Cav-1 is downregulated in fibroblasts cocultured with MCF7 cells. hTERT fibroblasts and MCF7 cells were cocultured for 5 days. Then, the cells were fixed and immunostained with antibodies directed against Cav-1 (red) and cytokeratin 8/18 (green, labeling MCF7 cells). Nuclei were counterstained with DAPI (Blue). As controls, fibroblast monocultures were fixed and stained in parallel. Representative images from confocal cross sections are shown. Note that Cav-1 is greatly downregulated in fibroblasts cocultured with MCF7 cells, as compared with fibroblast monocultures. Importantly, images were acquired using identical exposure settings. The white arrow points at the nucleus of a Cav-1-negative fibroblast (K8-18 negative). To better appreciate differences in Cav-1 expression, left part shows the red channel only. Original magnification, 40 $\times$. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (67). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

Oxidative Stress Promotes Tumor-Stroma Coevolution

To understand the mechanism(s) underlying a loss of Cav-1 expression in the tumor stroma, we created a novel coculture system using fibroblasts and cancer cells. In this model system, MCF7 human breast cancer cells are cocultured with immortalized fibroblasts under low-mitogen conditions for a period of up to 5 days. Most importantly, under these conditions of coculture, MCF7 cells downregulated the expression of Cav-1 in adjacent CAFs (Fig. 10). Mechanistically, a loss of Cav-1 in stromal fibroblasts was associated with certain phenotypic changes, such as the increased expression of myofibroblast markers, the increased secretion of ECM proteins, and activated TGF- β signaling, consistent with a CAF phenotype (67). We speculated that a loss of Cav-1 was due to increased protein degradation or turnover. In accordance with this hypothesis, pretreatment with chloroquine (a lysosomal inhibitor) prevented the loss of stromal fibroblast Cav-1 (67). These results indicate that Cav-1 is downregulated *via* lysosomal degradation during autophagy, a well-known stress response.

What is the nature of the stressor? How do cancer cells activate autophagy in adjacent stromal fibroblasts? One possibility is that cancer cells induce oxidative stress in fibroblasts

via a paracrine mechanism. To test this hypothesis directly, we treated MCF7-fibroblast cocultures with antioxidants and monitored the expression of Cav-1 in stromal fibroblasts. In this context, pretreatment with antioxidants (such as NAC, metformin, and quercetin) was indeed sufficient to prevent the loss of Cav-1 in fibroblasts, as predicted (Figs. 11–13). Thus, MCF7 cancer cells induce the autophagic degradation of Cav-1 *via* paracrine oxidative stress (66).

To better understand the mechanism(s) by which cancer epithelial cells promote the CAF phenotype, we further examined the role of oxidative stress as an initial trigger. Using the coculture system, we showed that Cav-1 downregulation is dependent on ROS in a feed-forward mechanism, where increased ROS leads to decreased Cav-1 and decreased Cav-1 leads to increased ROS (66). To validate the effect of ROS alone, homotypic cultures of fibroblasts were treated with a glutathione synthase inhibitor (namely buthionine sulfoxide [BSO]) to synthetically increase ROS (66). BSO treatment caused Cav-1 downregulation in a dose-dependent manner (66). Furthermore, we showed that under coculture conditions, the increase in ROS production in fibroblasts leads to mitochondrial dysfunction and a switch toward glycolytic metabolism, both specifically in fibroblasts (66). ROS production in fibroblasts also affected the cancer epithelial cells, *via* a bystander effect, causing genomic instability and aneuploidy; however, mitochondrial function and mass were both increased in the cancer cells (66). To validate that the observed mitochondrial biogenesis in cancer cells came as a consequence of the coculture with glycolytic fibroblasts, MCF7 cancer cells alone were treated with L-lactate to mimic the coculture conditions (66). Remarkably, L-lactate treatment was indeed sufficient to induce mitochondrial biogenesis in MCF7 cancer cells (66, 68).

Taken together, these findings have allowed us construct a new two-compartment metabolic model for the paracrine interactions between CAFs and cancer epithelial cells (Figs. 6 and 7). In this model, cancer cells promote oxidative stress in neighboring CAFs *via* NO overproduction, leading to mitochondrial dysfunction and the loss of Cav-1. This triggering event then further promotes the production of ROS by the CAFs. In turn, such stromal ROS production has a bystander effect in the cancer cells, leading to increased DNA damage and aneuploidy. Mitochondrial dysfunction in CAFs causes autophagy and mitophagy, leading to the reverse Warburg effect, by increasing HIF1- α and NF- κ B activation. The reverse Warburg effect in the CAFs creates a nutrient-rich microenvironment to directly feed cancer cells, *via* metabolic coupling. In addition, cancer cells mount an antioxidant defense, by upregulating antiapoptotic proteins (TIGAR) and antioxidant enzymes (peroxiredoxin-1) (66, 68).

In order to maximize treatment benefits, new biomarkers (such as stromal Cav-1) will be required to predict which cancer patients will respond best to antioxidant-based therapies and/or autophagy inhibitors. Importantly, the recent study by Nechuta *et al.* shows that antioxidant therapy can significantly reduce breast cancer recurrence and mortality (76). Reductions in mitochondrial stress in both cancer and stroma cells may be beneficial for preventing tumor progression and metastasis. Ultimately, clinical adoption of this new strategy could change current thinking on how we treat cancer patients.

FIG. 11. Breast cancer cells induce ROS production in fibroblasts, driving stromal Cav-1 downregulation: rescue with antioxidants. (A) ROS are elevated in fibroblasts cocultured with MCF7 cells. To detect ROS generation, CM-H2DCFDA staining (green) was performed on hTERT fibroblasts cocultured with MCF7 cells. Also, monocultures of hTERT fibroblasts and MCF7 cells were stained in parallel. Cells were counterstained with Hoechst nuclear stain (blue). Samples were then immediately imaged using a 488 nm excitation wavelength. As a critical control, in a parallel set of experiments, cells were preincubated with the ROS scavenger N-acetylcysteine (NAC). Note that ROS are generated mainly in cocultured fibroblasts (upper middle panel) and NAC treatment completely abrogates ROS production. Minimal amounts of ROS were detected in singly cultured cells. Importantly, images were acquired using identical exposure settings. Original magnification, 20 $\times$. (B) Treatment with the ROS scavenger NAC restores Cav-1 expression in cocultured fibroblasts. Day-5 fibroblast-MCF7 cocultures were incubated with the ROS scavenger NAC (10 mM, right panels) or with vehicle alone (left panels). Upper panels: Cocultures were fixed and immunostained with anti-Cav-1 (red) and anti-K8/18 (green, detecting tumor epithelial cells) antibodies. DAPI was used to stain nuclei (blue). Note that Cav-1 levels are decreased in fibroblasts in coculture (left upper panel) and the ROS scavenger NAC blocks the Cav-1 downregulation (right upper panel). Lower panels: In a parallel experiment, CM-H2DCFDA (green) was used to detect ROS generation. Cells were stained with Hoechst nuclear stain (blue). Importantly, images were acquired using identical exposure settings. Original magnification, 40 $\times$ for upper panels, 20 $\times$ for lower panels. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (66). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

As a critical control, in a parallel set of experiments, cells were preincubated with the ROS scavenger N-acetylcysteine (NAC). Note that ROS are generated mainly in cocultured fibroblasts (upper middle panel) and NAC treatment completely abrogates ROS production. Minimal amounts of ROS were detected in singly cultured cells. Importantly, images were acquired using identical exposure settings. Original magnification, 20 $\times$. (B) Treatment with the ROS scavenger NAC restores Cav-1 expression in cocultured fibroblasts. Day-5 fibroblast-MCF7 cocultures were incubated with the ROS scavenger NAC (10 mM, right panels) or with vehicle alone (left panels). Upper panels: Cocultures were fixed and immunostained with anti-Cav-1 (red) and anti-K8/18 (green, detecting tumor epithelial cells) antibodies. DAPI was used to stain nuclei (blue). Note that Cav-1 levels are decreased in fibroblasts in coculture (left upper panel) and the ROS scavenger NAC blocks the Cav-1 downregulation (right upper panel). Lower panels: In a parallel experiment, CM-H2DCFDA (green) was used to detect ROS generation. Cells were stained with Hoechst nuclear stain (blue). Importantly, images were acquired using identical exposure settings. Original magnification, 40 $\times$ for upper panels, 20 $\times$ for lower panels. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (66). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

FIG. 12. Breast cancer cells mount an antioxidant defense when cocultured with fibroblasts. Increased expression of peroxiredoxin-1 in cocultured MCF7 cells. Day-5 cocultures of hTERT fibroblasts and MCF7 cells and the corresponding homotypic cultures were immunostained with anti-peroxiredoxin-1 (red) and anti-K8/18 (green, detecting tumor epithelial cells) antibodies. DAPI was used to stain nuclei (blue). Upper panels show only the red channel to appreciate peroxiredoxin-1 staining, while the lower panels show the merged images. Note that the expression level of peroxiredoxin-1 is very low in homotypic cultures of fibroblasts and MCF7 cells. However, peroxiredoxin-1 levels are greatly increased in cocultured MCF7 cells. Importantly, images were acquired using identical exposure settings. Original magnification, 20 $\times$. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (66). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

FIG. 13. Rescue of oxidative stress induced DNA damage in fibroblast-MCF7 cell cocultures with NAC and L-NAME. Treatment with NAC and L-NAME abolishes DNA double-strand breaks in coculture. Day-2 cocultures of hTERT fibroblasts and MCF7 cells were treated with 10 mM NAC or with 20 mM L-NAME or with vehicle alone (H₂O) for 72 h. Then, cells were immunostained with anti-gamma-H2AX (red) antibodies. DAPI was used to stain nuclei (blue). Upper panels show only the red channel to appreciate gamma-H2AX staining, while the lower panels show nuclei staining. High levels of DNA double-strand breaks are detected in cocultured cells. Note that treatment with NAC and L-NAME abolishes DNA double-strand breaks in cocultured cells. Importantly, images were acquired using identical exposure settings. Original magnification, 40 $\times$. Modified and reproduced with permission from Martinez-Outschoorn *et al.* (66). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

The Reverse Warburg Effect: A Consequence of Autophagy in the Tumor Stroma

To begin to understand metabolism within the tumor microenvironment, the mammary fat pads of WT and Cav-1-deficient mice were subjected to an unbiased metabolomic analysis. As a result of this comprehensive analysis, ~200 metabolites were observed, and ~100 of them were seen to be increased in Cav-1^{-/-} null mice (86), consistent with a major catabolic phenotype. Of particular interest, there was a significant increase (~3–4 fold) in the levels of 3-hydroxy-butyrate (a ketone body) and asymmetric dimethyl arginine (ADMA), which are metabolites that are indicative of mitochondrial dysfunction and oxidative stress in the mammary fat pads of Cav-1^{-/-}-deficient mice (86).

These findings prompted us to reinterrogate the transcriptional profiling of Cav-1-deficient MSCs, with a focus on particular metabolic pathways, such as autophagy, mitophagy, and lysosomal enzyme expression (86). In addition, microRNAs (miRs) were also analyzed, since they have been implicated in both cancer initiation and progression (59). Interestingly, the top two miRs induced in Cav-1^{-/-} mesenchymal stromal cells, miR31 and miR34c, are functionally associated with HIF1- α activation and oxidative stress, respectively (86). HIF1- α activation and oxidative stress are both known to be important for the induction of autophagy (7, 69). To further validate our findings, we next used transcriptional profiling data from human breast cancer tumors and showed that these processes are indeed present within human tumor stroma, as well (87). The most important observation in this study is that extensive catabolism in the tumor stroma could directly feed the anabolic growth of cancer cells, *via* this parasitic mechanism (86). We have termed this new paradigm “The Autophagic Tumor Stroma Model of Cancer” (Figs. 6 and 7) (86).

These findings suggest that inhibition of autophagy in the tumor stroma will stop energy transfer to epithelial cancer cells, thereby inhibiting tumor growth. In an analogous way, autophagy induction in epithelial cancer cells should also halt tumor growth, by preventing cancer cells from using recycled nutrients. This provides a rational explanation for the “Au-

tophagy Paradox” (31) in cancer, since both blocking and promoting autophagy, with systemic therapies, has been experimentally shown to stop tumor growth.

In a follow-up study, we provided functional evidence to demonstrate that ketones and lactate fuel tumor growth and metastasis *in vivo* (11). A xenograft mouse model of human breast cancer (MDA-MB-231 cells) was used to study the impact of systemic administration of L-lactate and 3-hydroxy-butyrate (a ketone body) on tumor growth, progression, and metastasis (11). This study demonstrated that the two metabolites promote tumor growth and metastasis, independent of angiogenesis (11). In addition, it also demonstrated that epithelial cancer cells shift their metabolism toward mitochondrial oxidative phosphorylation, compared to the adjacent stroma cells which shift their metabolism toward glycolysis (11). Further, we suggest that oncology surgeons may wish to reconsider using Lactate Ringer’s solution in cancer patients, as it may promote tumor recurrence and metastasis (11).

Further evidence for the autophagic tumor stroma model of cancer was observed in electron micrographs of cocultures of fibroblasts with MCF7 breast cancer epithelial cells. An abundance of lysosomes and autophagosomes actively degrading mitochondrial-like structures was observed within CAFs and, in parallel, the MCF7 cells displayed extensive and healthy mitochondria (68).

To further delineate the molecular mechanism(s) by which Cav-1 expression is controlled in this process, it was shown that hypoxic conditions were sufficient to induce the autophagic degradation of Cav-1. Also, siRNA-mediated downregulation of Cav-1 expression was sufficient to induce various autophagy/mitophagy and lysosomal markers (68). Similarly, we also showed that cancer cells activate HIF1- α - and NFkB-based luciferase reporters in adjacent CAFs, *via* a paracrine mechanism (68). Activation of proautophagic HIF1- α is sufficient to induce Cav-1 downregulation in fibroblasts under hypoxia (68). Interestingly, cancer cells under coculture conditions show reductions in apoptosis and the upregulation of the antiapoptotic protein TIGAR (68), indicating that they functionally benefit from the recycled nutrients provided by autophagic fibroblasts.

FIG. 14. Induction of MCT4 in CAFs is due to oxidative stress and is prevented by antioxidants. MCF7 cells were cocultured with fibroblasts and then we observed the distribution of MCT4 (red) by fluorescence microscopy. Since MCT4 expression is controlled by HIF1 and HIF1 is also activated by pseudohypoxia (oxidative stress), we assessed the effects of antioxidants on this process. Note that treatment with NAC (10 mM), a powerful antioxidant, is sufficient to block that upregulation of MCT4 in CAFs, as predicted. Epithelial cancer cells were visualized by keratin staining (green). Modified and reproduced with permission from Whitaker-Menezes *et al.* (117). (To see this illustration in color, the reader is referred to the Web version of this article at www.liebertonline.com/ars).

Cancer Cells Fertilize the Tumor Microenvironment with Hydrogen Peroxide

Until recently, it remained unknown how cancer cells induce oxidative stress in adjacent stromal fibroblasts. What is the triggering event? Is it growth factor mediated or due to the secretion of ROS directly from cancer cells?

To address this issue, we used the MCF7–fibroblast coculture system. We observed that cancer cells initially secrete hydrogen peroxide, which then triggers oxidative stress in neighboring fibroblasts (61). More specifically, at 2 days of coculture, most of the ROS production occurred in MCF7 cells (61). This ROS production was reduced to baseline levels by coincubation with extracellular catalase, identifying the predominant ROS as hydrogen peroxide (61). In contrast, by day 5, most of the ROS production occurred in the CAFs (61). Thus, oxidative stress is contagious and is propagated laterally from cancer cells to adjacent fibroblasts. Importantly, we observed using this MCF7–fibroblast coculture system that hydrogen peroxide secretion activates NFkB and HIF1 in CAFs, driving stromal inflammation and aerobic glycolysis, as well as autophagy. As such, hydrogen peroxide helps to produce glycolytic fibroblasts which feed hungry oxidative cancer cells, actively fertilizing the tumor microenvironment (61).

Most importantly, under coculture conditions, treatment with catalase (to neutralize hydrogen peroxide) dramatically induced apoptosis in cocultured MCF7 cancer cells (61). Mechanistically, this may explain why catalase therapy in pre-clinical models prevents both tumor recurrence and metastasis (48, 49, 77–81), as it cuts off the fuel supply.

Consistent with these findings, MCT4 protein expression (a marker of aerobic glycolysis and lactate production) in CAFs is induced by oxidative stress and can be prevented with antioxidants, such as NAC (117) (Fig. 14).

Glutaminolysis and Autophagy in the Tumor Stroma: A Vicious Cycle

Previous studies have shown that cancer cells can become addicted to glutamine. After entering the cell, glutamine is converted to glutamate, enters the TCA cycle, which results in the production of ATP by oxidative phosphorylation (21). Ammonia is produced as a by-product of this reaction, which in turn can act as an inducer of autophagy (32, 33, 65). In our laboratory, we have shown that increased autophagy (as a result of a loss of stromal Cav-1) results in increased glutamine levels in the stromal compartment (86). The glutamine produced as a result of autophagy, in the tumor microenvironment, could then fuel the growth of adjacent cancer cells, while the ammonia by-product could help to maintain the autophagic production of glutamine. This vicious cycle fits well with the autophagic tumor stroma model of cancer, (86) where energy-rich recycled nutrients (L-lactate, ketones, and glutamine) fuel oxidative mitochondrial metabolism in cancer cells.

Conclusions

Here, we have highlighted two new models for understanding tumor metabolism, (i) the reverse Warburg effect and (ii) the autophagic tumor stroma model of cancer, which suggest that an intimate relationship exists between tumor cells and their associated fibroblasts. It is now clear that

both cell types (epithelial cancer cells and fibroblasts) functionally create the cancer microenvironment *via* hydrogen peroxide and oxidative stress, even though prior studies did not recognize that these two compartments are metabolically coupled.

What these new models bring to “the table” is the establishment of new therapeutic avenues for fighting cancer. These new paradigms provide novel targets for the development of more potent anticancer therapies, either by blocking energy transfer between cancer cells and fibroblasts (using MCT inhibitors), or by preventing ROS production and oxidative stress (with powerful antioxidants), or by inhibiting autophagy in CAFs and promoting autophagy in cancer cells, thereby metabolically uncoupling tumor cells from their surrounding stroma.

In this context, existing drugs, such as metformin and chloroquine, antioxidant supplements, such as quercetin or NAC, can have a significant impact. Similarly, new drugs can be developed, as is the case for two new MCT1 inhibitors (from AstraZeneca). Importantly, these new metabolic models will foster the development of novel biomarkers, and corresponding therapies, to fulfill the goal of personalized cancer medicine.

Acknowledgments

Federica Sotgia and her laboratory were supported by grants from the W.W. Smith Charitable Trust, the Breast Cancer Alliance (BCA), and a Research Scholar Grant from the American Cancer Society (ACS). Michael P. Lisanti was supported by grants from the NIH/NCI (R01-CA-080250, R01-CA-098779, R01-CA-120876, and R01-AR-055660), and the Susan G. Komen Breast Cancer Foundation. Isabelle Mercier was the recipient of a Post-doctoral Fellowship from the Susan G. Komen Breast Cancer Foundation. Richard G. Pestell was supported by grants from the NIH/NCI (R01-CA-70896, R01-CA-75503, R01-CA-86072, and R01-CA-107382) and the Dr. Ralph and Marian C. Falk Medical Research Trust. The Kimmel Cancer Center was supported by the NIH/NCI Cancer Center Core grant P30-CA-56036 (to Richard G. Pestell). Funds were also contributed by the Margaret Q. Landenberger Research Foundation (to Michael P. Lisanti). This project is funded, in part, under a grant with the Pennsylvania Department of Health (to Michael P. Lisanti and Federica Sotgia). The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions. This work was also supported, in part, by a Centre grant in Manchester from Breakthrough Breast Cancer in the United Kingdom (to Anthony Howell) and an Advanced ERC Grant from the European Research Council.

References

1. Amatangelo MD, Bassi DE, Klein-Szanto AJP, and Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. *Am J Pathol* 167: 475–488, 2005.
2. American Cancer Society. *Breast Cancer Facts & Figures 2009–2010*. Atlanta: American Cancer Society, Inc., 2009.
3. Andre F, Berrada N, and Desmedt C. Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. *Curr Opin Oncol* 22: 547–551, 2010.

4. Apel A, Herr I, Schwarz H, Rodemann HP, and Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res* 68: 1485–1494, 2008.
5. Baehrecke EH. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 6: 505–510, 2005.
6. Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL, and Teicher BA. Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. *Int J Oncol* 34: 619–627, 2009.
7. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, and Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. *Mol Cell Biol* 29: 2570–2581, 2009.
8. Berges A, Van Nassauw L, Bosmans J, Timmermans J-P, and Vrints C. Role of nitric oxide and oxidative stress in ischaemic myocardial injury and preconditioning. *Acta Cardiol* 58: 119–132, 2003.
9. Bergfeld SA and DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. *Cancer Metastasis Rev* 29: 249–261, 2010.
10. Bolaños JP, Peuchen S, Heales SJ, Land JM, and Clark JB. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. *J Neurochem* 63: 910–916, 1994.
11. Bonuccelli G, Tsigirgos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, and Lisanti MP. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle* 9: 3506–3514, 2010.
12. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, and Lisanti MP. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. *Cell Cycle* 9: 1960–1971, 2010.
13. Bosch M, Marí M, Herms A, Fernández A, Fajardo A, Kassan A, Giral A, Colell A, Balgoma D, Barbero E, González-Moreno E, Matias N, Tebar F, Balsinde J, Camps M, Enrich C, Gross SP, García-Ruiz C, Pérez-Navarro E, Fernández-Checa JC, and Pol A. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. *Curr Biol* 21: 681–686, 2011.
14. Bouras T, Lisanti MP, and Pestell RG. Caveolin-1 in breast cancer. *Cancer Biol Ther* 3: 931–941, 2004.
15. Castro L, Demicheli V, Tórtora V, and Radi R. Mitochondrial protein tyrosine nitration. *Free Radic Res* 45: 37–52, 2011.
16. Cirino G, Distrutti E, and Wallace JL. Nitric oxide and inflammation. *Inflamm Allergy Drug Targets* 5: 115–119, 2006.
17. Codogno P and Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. *Cell Death Differ* 12 Suppl 2: 1509–1518, 2005.
18. Cohen AW, Hnasko R, Schubert W, and Lisanti MP. Role of caveolae and caveolins in health and disease. *Physiol Rev* 84: 1341–1379, 2004.
19. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, and Lisanti MP. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. *Diabetes* 53: 1261–1270, 2004.
20. Cohen AW, Schubert W, Brasaemle DL, Scherer PE, and Lisanti MP. Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. *Diabetes* 54: 679–686, 2005.
21. Dang CV. MYC, microRNAs and Glutamine Addiction in Cancers. *Cell Cycle* 8: 3243–3245, 2009.
22. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab* 7: 11–20, 2008.
23. DeCossé JJ, Gossens CL, Kuzma JF, and Unsworth BR. Breast cancer: induction of differentiation by embryonic tissue. *Science* 181: 1057–1058, 1973.
24. DeCossé JJ, Gossens C, Kuzma JF, and Unsworth BR. Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma *in vitro*. *J Natl Cancer Inst* 54: 913–922, 1975.
25. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, and White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 10: 51–64, 2006.
26. DeYoung MP, Horak P, Sofer A, Sgroi D, and Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. *Genes Dev* 22: 239–251, 2008.
27. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, and Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. *Cell cycle (Georgetown, TX)* 8: 2420–2424, 2009.
28. Dolled-Filhart MP, Rimm DL, and Stroobant P. Quantitative *in situ* cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis. *Personalized Med* 2: 291–300, 2005.
29. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med* 315: 1650–1659, 1986.
30. Eakin RT, Morgan LO, Gregg CT, and Matwiyoff NA. Carbon-13 nuclear magnetic resonance spectroscopy of living cells and their metabolism of a specifically labeled ¹³C substrate. *FEBS Lett* 28: 259–264, 1972.
31. Eisenberg-Lerner A and Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. *Apoptosis* 14: 376–391, 2009.
32. Eng CH and Abraham RT. Glutaminolysis yields a metabolic by-product that stimulates autophagy. *Autophagy* 6: 968–970, 2010.
33. Eng CH, Yu K, Lucas J, White E, and Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Sci Signal* 3: ra31, 2010.
34. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. *J Biol Chem* 272: 16374–16381, 1997.
35. Fantin VR and Leder P. Mitochondriotoxic compounds for cancer therapy. *Oncogene* 25: 4787–4797, 2006.
36. Fernández MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton RG, and Pol A. Caveolin-1 is essential for liver regeneration. *Science* 313: 1628–1632, 2006.
37. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. *Radiother Oncol* 92: 329–333, 2009.
38. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A,

- Hallett M, and Park M. Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med* 14: 518–527, 2008.
39. Fiucci G, Ravid D, Reich R, and Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. *Oncogene* 21: 2365–2375, 2002.
40. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, and Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. *EMBO J* 17: 6633–6648, 1998.
41. García-Cardeña G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, and Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain *in vivo*. *J Biol Chem* 272: 25437–25440, 1997.
42. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, and Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. *Cancer Res* 70: 6945–6956, 2010.
43. Goetz JG, Lajoie P, Wiseman SM, and Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. *Cancer Metastasis Rev* 27: 715–735, 2008.
44. Haviv I, Polyak K, Qiu W, Hu M, and Campbell I. Origin of carcinoma associated fibroblasts. *Cell Cycle* 8: 589–595, 2009.
45. Heales SJ, Bolaños JP, Stewart VC, Brookes PS, Land JM, and Clark JB. Nitric oxide, mitochondria and neurological disease. *Biochim Biophys Acta* 1410: 215–228, 1999.
46. Henning T, Kraus M, Brischwein M, Otto AM, and Wolf B. Relevance of tumor microenvironment for progression, therapy and drug development. *Anticancer Drugs* 15: 7–14, 2004.
47. Holmes FL. *Hans Krebs: the Formation of a Scientific Life, 1900–1933*. Oxford University Press, Oxford, UK 1991.
48. Hyoudou K, Nishikawa M, Ikemura M, Kobayashi Y, Mendelsohn A, Miyazaki N, Tabata Y, Yamashita F, and Hashida M. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. *J Controlled Release* 137: 110–115, 2009.
49. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, and Hashida M. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. *Free Radic Biol Med* 41: 1449–1458, 2006.
50. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, and Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. *Cancer Sci* 101: 293–299, 2010.
51. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang K-Y, Sasaguri Y, Nishizawa S, and Kohno K. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. *Cancer Sci* 102: 1007–1013, 2011.
52. Ju H, Zou R, Venema VJ, and Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. *J Biol Chem* 272: 18522–18525, 1997.
53. Kalluri R and Zeisberg M. Fibroblasts in cancer. *Nat Rev Cancer* 6: 392–401, 2006.
54. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, and Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. *Eur J Cancer* 39: 184–191, 2003.
55. Knott AB and Bossy-Wetzel E. Impact of nitric oxide on metabolism in health and age-related disease. *Diabetes Obes Metab* 12 Suppl 2: 126–133, 2010.
56. Koleske AJ, Baltimore D, and Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. *Proc Natl Acad Sci U S A* 92: 1381–1385, 1995.
57. Koo JS, Park S, Kim SI, Lee S, and Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. *Tumour Biol* 32: 787–799, 2011.
58. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. *Cancer cell* 13: 472–482, 2008.
59. Le Quesne J and Caldas C. Micro-RNAs and breast cancer. *Mol Oncol* 4: 230–241, 2010.
60. Lee SW, Reimer CL, Oh P, Campbell DB, and Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. *Oncogene* 16: 1391–1397, 1998.
61. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, and Sotgia F. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer.” *Cell Cycle* 10: 2440–2449, 2011.
62. Magistretti PJ. Role of glutamate in neuron-glia metabolic coupling. *Am J Clin Nutr* 90: 875S–880S, 2009.
63. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. *Exp Physiol* 96: 407–410, 2011.
64. Magistretti PJ and Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. *Mol Psychiatry* 1: 445–452, 1996.
65. Mariño G and Kroemer G. Ammonia: a diffusible factor released by proliferating cells that induces autophagy. *Sci Signal* 3: pe19, 2010.
66. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F and Lisanti MP. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. *Cell Cycle* 9: 3256–3276, 2010.
67. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP and Sotgia F. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. *Cell Cycle* 9: 2423–2433, 2010.
68. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP and Sotgia F. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. *Cell Cycle* 9: 3515–3533, 2010.
69. Mazure NM and Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? *Curr Opin Cell Biol* 22: 177–180, 2010.
70. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin J-F, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, and Lisanti MP. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and RB tumor suppressor functional inactivation:

- implications for the response to hormonal therapy. *Cancer Biol Ther* 7: 1212–1225, 2008.
71. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F, and Lisanti MP. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. *Cell Cycle* 9: 2412–2422, 2010.
 72. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, and Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. *Cancer Res* 68: 4331–4339, 2008.
 73. Mizushima N. Autophagy: process and function. *Genes Dev* 21: 2861–2873, 2007.
 74. Mizushima N, Levine B, Cuervo AM, and Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature* 451: 1069–1075, 2008.
 75. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, and Saavedra E. Energy metabolism in tumor cells. *FEBS J* 274: 1393–1418, 2007.
 76. Nechuta S, Lu W, Chen Z, Zheng Y, Gu K, Cai H, Zheng W, and Shu XO. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev* 20: 262–271, 2011.
 77. Nishikawa M. Reactive oxygen species in tumor metastasis. *Cancer Lett* 266: 53–59, 2008.
 78. Nishikawa M and Hashida M. Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. *Expert Opin Drug Deliv* 3: 355–369, 2006.
 79. Nishikawa M, Hashida M, and Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. *Adv Drug Deliv Rev* 61: 319–326, 2009.
 80. Nishikawa M, Tamada A, Hyoudou K, Umeyama Y, Takahashi Y, Kobayashi Y, Kumai H, Ishida E, Staud F, Yabe Y, Takakura Y, Yamashita F, and Hashida M. Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. *Clin Exp Metastasis* 21: 213–221, 2004.
 81. Nishikawa M, Tamada A, Kumai H, Yamashita F, and Hashida M. Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. *Int J Cancer* 99: 474–479, 2002.
 82. Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, Kouzu Y, Koike H, Siiba M, Bukawa H, Yokoe H, Kubosawa H, and Tanzawa H. Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis. *Hum Pathol* 40: 83–91, 2009.
 83. Orimo A and Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. *Cell Cycle* 5: 1597–1601, 2006.
 84. Ozzello L. Ultrastructure of the human mammary gland. *Pathol Annu* 6: 1–59, 1971.
 85. Pasteur L. Experiments and novel views on the nature of fermentation. *Comp Rend Acad Sci* 89: 1260–1264, 1861.
 86. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F, and Lisanti MP. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. *Cell Cycle* 9: 3485–3505, 2010.
 87. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, and Lisanti MP. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the “reverse Warburg effect”: a transcriptional informatics analysis with validation. *Cell Cycle* 9: 2201–2219, 2010.
 88. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F, and Lisanti MP. Transcriptional evidence for the “Reverse Warburg Effect” in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer’s disease, and “Neuron-Glia Metabolic Coupling.” *Aging (Albany, NY)* 2: 185–199, 2010.
 89. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Chenguang W, Fortina P, and Addya S. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell cycle* 8: 3984–4001, 2009.
 90. Pellerin L and Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. *Proc Natl Acad Sci U S A* 91: 10625–10629, 1994.
 91. Pietras K and Ostman A. Hallmarks of cancer: interactions with the tumor stroma. *Exp Cell Res* 316: 1324–1331, 2010.
 92. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, and Baltazar F. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. *Histopathology* 56: 860–867, 2010.
 93. Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SMM, Etlinger D, Moreira MAR, Jubé LF, Queiroz GS, Schmitt F, and Baltazar F. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. *Int J Gynecol Pathol* 27: 568–574, 2008.
 94. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VAF, Schmitt F, and Baltazar F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. *Virchows Arch* 452: 139–146, 2008.
 95. Pinilla SMR, Honrado E, Hardisson D, Benítez J, and Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. *Breast Cancer Res Treat* 99: 85–90, 2006.
 96. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, and West AB. Myofibroblasts. I. Paracrine cells important in health and disease. *Am J Physiol* 277: C1–C9, 1999.
 97. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, and West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. *Am J Physiol* 277: C183–C201, 1999.
 98. Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T, and Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. *Cancer Sci* 102: 1590–1596, 2011.
 99. Radi R, Rodriguez M, Castro L, and Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. *Arch Biochem Biophys* 308: 89–95, 1994.
 100. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, Edelman

- W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. *J Biol Chem* 276: 38121–38138, 2001.
101. Rodríguez-Enríquez S and Moreno-Sánchez R. Intermediary metabolism of fast-growth tumor cells. *Arch Med Res* 29: 1–12, 1998.
102. Rofstad EK, Mathiesen B, Kindem K, and Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. *Cancer Res* 66: 6699–6707, 2006.
103. Savage K, Lambros MBK, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CDM, Schmitt FC, Ashworth A, and Reis-Filho JS. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and *in situ* hybridization analysis. *Clin Cancer Res* 13: 90–101, 2007.
104. Schäfer M and Werner S. Cancer as an overheating wound: an old hypothesis revisited. *Nat Rev Mol Cell Biol* 9: 628–638, 2008.
105. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Bérout C, Demont J, Bouvier R, Schägger H, and Godinot C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. *Carcinogenesis* 23: 759–768, 2002.
106. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE, and Anderson RL. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. *Am J Pathol* 174: 2035–2043, 2009.
107. Sloan EK, Stanley KL, and Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. *Oncogene* 23: 7893–7897, 2004.
108. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, and Lisanti MP. Caveolin-1/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. *Am J Pathol* 174: 746–761, 2009.
109. Tsacopoulos M and Magistretti PJ. Metabolic coupling between glia and neurons. *J Neurosci* 16: 877–885, 1996.
110. Vander Heiden MG, Cantley LC, and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 324: 1029–1033, 2009.
111. Vaupel P, Okunieff P, and Neuringer LJ. Blood flow, tissue oxygenation, pH distribution, and energy metabolism of murine mammary adenocarcinomas during growth. *Adv Exp Med Biol* 248: 835–845, 1989.
112. Vered M, Allon I, Buchner A, and Dayan D. Stromal myofibroblasts and malignant transformation in a 4NQO rat tongue carcinogenesis model. *Oral Oncol* 43: 999–1006, 2007.
113. Vered M, Allon I, Buchner A, and Dayan D. Stromal myofibroblasts accompany modifications in the epithelial phenotype of tongue dysplastic and malignant lesions. *Cancer Microenviron* 2: 49–57, 2009.
114. Virchow R and Chance F. *Cellular Pathology as Based upon Physiological and Pathological Histology*. Philadelphia: J.B. Lippincott, 1863.
115. Wang M, Fudge K, Rhim JS, and Stearns ME. Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines. *Oncol Res* 8: 303–315, 1996.
116. Warburg O. On the origin of cancer cells. *Science (New York, NY)* 123: 309–314, 1956.
117. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, and Lisanti MP. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. *Cell Cycle* 10: 1772–1783, 2011.
118. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schöber H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schäfer R, and Sers C. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. *Am J Pathol* 159: 1635–1643, 2001.
119. Williams TM, Cheung MW-C, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, and Lisanti MP. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. *Mol Biol Cell* 14: 1027–1042, 2003.
120. Williams TM and Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. *Am J Physiol Cell Physiol* 288: C494–C506, 2005.
121. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, and Lisanti MP. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis *in vivo*. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. *J Biol Chem* 279: 51630–51646, 2004.
122. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, and Lisanti MP. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. *Am J Pathol* 169: 1784–1801, 2006.
123. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, and Lisanti MP. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. *Cancer Biol Ther* 8: 1071–1079, 2009.
124. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, and Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. *Cancer Biol Ther* 10: 135, 2010.
125. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, and Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. *Am J Pathol* 174: 2023–2034, 2009.
126. Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, Pavlides S, Ertel A, Sotgia F, and Lisanti MP. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. *Cell Cycle* 10: 1794–1809, 2011.
127. Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. *J Clin Invest* 119: 1429–1437, 2009.
128. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, and Semenza GL. Mitochondrial

- autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. *J Biol Chem* 283: 10892–10903, 2008.
129. Zhang Z-B, Cai L, Zheng S-G, Xiong Y, and Dong J-H. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. *Pathol Oncol Res* 15: 495–502, 2009.

Address correspondence to:
 Dr. Federica Sotgia
 Department of Cancer Biology
 Kimmel Cancer Center
 Thomas Jefferson University
 233 South 10th St.
 Philadelphia, PA 19107

E-mail: federica.sotgia@jefferson.edu

Dr. Michael P. Lisanti
 Department of Stem Cell Biology & Regenerative Medicine
 Kimmel Cancer Center
 Thomas Jefferson University
 233 South 10th St.
 Philadelphia, PA 19107

E-mail: michael.lisanti@kimmelcancercenter.org

Date of first submission to ARS Central, August 21, 2011; date of acceptance, September 1, 2011.

Abbreviations Used

2DG = 2-deoxy-glucose
 ADMA = asymmetric dimethyl arginine
 Cav-1 = caveolin-1
 BAT = brown adipose tissue
 BM = bone marrow
 CAFs = cancer-associated fibroblasts
 CK5/6 = cytokeratin 5/6
 DCIS = ductal carcinoma *in situ*
 ECM = extracellular matrix
 EGFR = epidermal growth factor receptor
 EMT = epithelial–mesenchymal transition
 ER = estrogen receptor
 HER2 = human EGF receptor 2
 HIF1- α = hypoxia-inducible transcription factor 1- α
 LN+ = lymph node positive
 MCT = monocarboxylate transporter
 miR = microRNA
 MMPs = matrix metalloproteinases
 MSCs = mesenchymal stem cells
 NAC = N-acetylcysteine
 NOS = nitric oxide synthase
 OXPHOS = oxidative phosphorylation
 PR = progesterone receptor
 ROS = reactive oxygen species
 TCA = tricarboxylic acid
 TMA = tumor microarray
 VEGF = vascular endothelial growth factor
 WAT = white adipose tissue